Celltrion completes transfer of Takeda-acquired products
By Ji Yong Jun | translator Alice Kang
22.01.26 12:01:08
가나다라
0
Celltrion secures product license of key products in Korea in 1 year after acquiring Takeda’s products
Products that sold ₩70 billion’s worth in the previous year to be incorporated into Celltrion Pharm’s sales performance
▲(Clockwise from the left) Nesina, Actos, Edarbi, Albothyl, Whituben, Nesina Met (Pic=MFDS)
The transfer of rights for Takeda Pharmaceutical’s products that Celltrion acquired is now complete. The license of OTCs and diabetes drugs that were sold under Takeda Pharmaceutical’s name has been changed to Celltrion Pharm.According to the industry on the 26th, the ownership of the license for Nesina Act Tab 12.5/30mg has been changed from Takeda Pharmaceutical to Celltrion recently. With the change, the company completed changing the license rights for drugs acquired from Takeda Pharmaceutical. This completion comes in around a year since Celltrion acquired the rights for some Takeda pharmaceutical products in the Asia Pacific region.
In December 2020, Celltrion acquired the right
Ji Yong Jun(jun1@dailypharm.com)
If you want to see the full article, please JOIN US (click)